Skip to main content
Tourmaline Bio, Inc. logo

Tourmaline Bio, Inc. — Investor Relations & Filings

Ticker · TRML ISIN · US87410C1045 US Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2025-03-13 Capital/Financing Update
Country US United States of America
Listing US TRML

About Tourmaline Bio, Inc.

https://www.tourmalinebio.com/

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with life-altering inflammatory and immune diseases. The company's lead asset is pacibekitug, a monoclonal antibody that targets the interleukin-6 (IL-6) cytokine, a key driver of inflammation. Pacibekitug is being developed as a potential treatment for a range of conditions, with a primary focus on atherosclerotic cardiovascular disease (ASCVD) and other severe autoimmune and inflammatory disorders, aiming to establish a new standard of care in areas with high unmet medical need.

Recent filings

Filing Released Lang Actions
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Tourmaline Bio, Inc. on March 13, 2025. Form S-8 is used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. The document includes details about the registration of additional shares under the 2023 Equity Incentive Plan and the 2023 Employee Stock Purchase Plan. It references incorporation by reference of the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, but this document itself is not the Annual Report. It is a registration statement related to capital raising through employee stock plans, which fits the category of Capital/Financing Update. The document is lengthy (over 10,000 characters) and contains substantive information about the registration of shares, not merely an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-03-13 English
10-K
Annual Report FY 2024
2025-03-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated March 13, 2025, for Tourmaline Bio, Inc. It announces the issuance of a press release containing recent business highlights and financial results for the quarter and year ended December 31, 2024. The document itself does not contain the financial results but furnishes the press release as an exhibit. The text explicitly states that the information is being furnished and is not "filed" for purposes of Section 18, indicating this is an announcement rather than the full earnings report. The length of the document is 3958 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a current report announcing the release of financial results but does not contain the full financial data itself.
2025-03-13 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-14 English
FORM 4
Director's Dealing
2025-02-04 English
FORM 4
Director's Dealing
2025-01-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.